Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.77 |
| ▸ | CNR1 | P21554 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | PPARG | P37231 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | HTR2A | P28223 | 2/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.77 |
| ▸ | ACHE | P22303 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209011 | 0.90 | MAPT (0.60) | PPARACNR1MEN1KMT2ACYP1A2 | |
| Fenofibrate SCHEMBL3876232 | 0.87 | PPARA (1.00) | PPARACNR1MEN1KMT2ACYP1A2 | |
| Fenofibrate SCHEMBL4670 | 0.87 | PPARA (1.00) | PPARACNR1MEN1KMT2ACYP1A2 | |
| Fenofibrate SCHEMBL22209064 | 0.86 | PPARA (0.97) | PPARACNR1MEN1KMT2ACYP1A2 | |
| Fenofibrate SCHEMBL21758490 | 0.86 | PPARA (0.97) | PPARACNR1MEN1KMT2ACYP1A2 | |
| Fenofibrate SCHEMBL29262792 | 0.86 | PPARA (0.97) | PPARACNR1MEN1KMT2ACYP1A2 | |
| Fenofibrate SCHEMBL29262793 | 0.86 | PPARA (0.97) | PPARACNR1MEN1KMT2ACYP1A2 | |
| Fenofibrate SCHEMBL27847067 | 0.86 | PPARA (0.97) | PPARACNR1MEN1KMT2ACYP1A2 | |
| SCHEMBL31084127 | 0.84 | PPARA (0.92) | PPARACNR1MEN1KMT2ACYP1A2 | |
| SCHEMBL31084128 | 0.84 | PPARA (0.92) | PPARACNR1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844078-B1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | BEND RES INC (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9387252-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9387252-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140171441-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | BEND RESEARCH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171441-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | BEND RESEARCH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2548894-A1 | Pharmaceutical compositions with enhanced performance | Bend Research, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20080064763-A1 | solid amorphous dispersions of low-solubility drugs and hydroxypropyl methyl cellulose alkanyl phthalate; enhance physical stability, absorption of drug in vivo, drug's bioavailability; fluvastatin HMG-CoA reductase inhibitor | BEND RESEARCH, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064763-A1 | solid amorphous dispersions of low-solubility drugs and hydroxypropyl methyl cellulose alkanyl phthalate; enhance physical stability, absorption of drug in vivo, drug's bioavailability; fluvastatin HMG-CoA reductase inhibitor | BEND RESEARCH, INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2006082518-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | PFIZER PRODUCTS INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064763-A1 | solid amorphous dispersions of low-solubility drugs and hydroxypropyl methyl cellulose alkanyl phthalate; enhance physical stability, absorption of drug in vivo, drug's bioavailability; fluvastatin HMG-CoA reductase inhibitor | HMGCR, CYP3A43, CYP4F3 | PPARA 766/4885CNR1 3293/4885MEN1 3519/4885 |
| US-20140171441-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | CYP3A43, CYP3A7, CYP3A4 | PPARA 990/4885CNR1 2950/4885MEN1 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.